Despite the role of glutamine metabolism in promoting tumor progression being well documented [4], the potential roles of these transporters are less investigated particularly in terms of endocrine resistance in luminal breast cancer, apart from SLC38A2 and SLC7A5 [23, 24]. Here, SLC38A2 is linked to breast carcinoma.